We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy.
- Authors
Chu, Tianqing; Yuan, Jie; Lu, Jun; Nie, Wei; Zhong, Runbo; Zhang, Bo; Zhang, Wei; Shi, Chunlei; Qian, Jialin; Zhang, Yanwei; Zhang, Xueyan; Teng, Jiajun; Gao, Zhiqiang; Lou, Yuqing; Li, Jiaqi; Qiang, Huiping; Zhang, Chao; Li, Jin; Xia, Xuefeng; Zhong, Hua
- Abstract
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy (B) Progression-free survival (PFS) enrichment for the high level of MSAF patients (MSAF-H) and low level of MSAF patients (MSAF-L). Furthermore, Kaplan-Meier curve analysis showed that the NSCLC patients with high MSAF received a median PFS of 836 days, while the patients with low MSAF received a median PFS of 322 days at BL ( I p i = .011; Figure 1C). Results suggested that the NSCLC patients with high MSAF received more PFS benefit than those with low MSAF the patients ( I p i = .029; Figure 2G).
- Subjects
NON-small-cell lung carcinoma; PROGRESSION-free survival; CANCER patients; CIRCULATING tumor DNA; ANLOTINIB
- Publication
Clinical & Translational Medicine, 2023, Vol 13, Issue 6, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.1277